Read what researchers wanted to find out and what it means in everyday words. Open the details if you want to see how a study was done. The product pages have a shorter explanation.
This library still contains examples, not checked research papers. We have not verified their sources or results. Do not use them to decide which product to take.
18 examples found
Example · source not checked
BPC-157 and repairing a tendon
An experiment with rats, not people.
What did they want to find out?
Did the connection between a tendon and bone repair differently with BPC-157?
What does this example say?
The example says this connection repaired faster than in the comparison group.
What does this mean for you?
A result in rats can help researchers ask new questions. It does not show that an injury in a person will heal faster.
What we still do not know
We have not verified the article behind this example. The summary does not provide proof of a benefit in people.
Show example study details (not verified)
These details come from an example summary. We have not checked the original paper. They are not proof that a product works or is safe.
Example summary: BPC-157 and tendon repair
Journal of Orthopaedic Research · 2021
How it was studied
Controlled animal model. n = 48 rats.
Original example finding
Accelerated tendon-bone repair compared with control in a controlled rodent model, according to the supplied summary.
Original example limitations
Unverified profile. No randomized human trials; extrapolation of doses to humans is not validated.
Terms explained
Tendon
Tissue that connects a muscle to a bone.
Comparison group
Another group used to compare what happened in the experiment.
This link opens PubMed's search site, not a checked paper for this summary.
Experiments with cells in a laboratory and with rodents, not people.
What did they want to find out?
Did thymosin beta-4 change how cells moved in repair experiments?
What does this example say?
The example says certain skin cells and blood-vessel cells moved more in these experiments.
What does this mean for you?
Watching how cells move helps researchers study repair. It does not show that a person will recover faster from an injury.
What we still do not know
We have not verified the article behind this example. Full thymosin beta-4 and a fragment called TB-500 are not the same thing. This summary does not prove a benefit from the fragment.
Show example study details (not verified)
These details come from an example summary. We have not checked the original paper. They are not proof that a product works or is safe.
Example summary: thymosin beta-4 and cell migration
Annals of the New York Academy of Sciences · 2012
How it was studied
In vitro and animal studies. Cell lines and rodent models.
Original example finding
Promotion of keratinocyte and endothelial cell migration in repair assays, according to the supplied summary.
Original example limitations
Unverified profile. Mechanistic work only, without performance outcomes.
Terms explained
Cell migration
Cells moving from one place to another.
In vitro
In a laboratory setting, outside a whole living organism.
This link opens PubMed's search site, not a checked paper for this summary.
Early research that includes a small group of people followed for a short time.
What did they want to find out?
Did Ipamorelin change how much growth hormone was released?
What does this example say?
The example says Ipamorelin increased growth hormone release.
What does this mean for you?
A change in a hormone measurement is not the same as feeling better. It does not prove better sleep, more muscle or faster recovery.
What we still do not know
We have not verified the article behind this example. The group was small and follow-up was short. The summary gives no results for changes in the amount of body fat or muscle.
Show example study details (not verified)
These details come from an example summary. We have not checked the original paper. They are not proof that a product works or is safe.
Example summary: Ipamorelin and GH release
European Journal of Endocrinology · 1998
How it was studied
Preclinical research and initial human dosing. n = 24 human participants.
Original example finding
Dose-dependent GH release, without a significant increase in ACTH or cortisol, according to the supplied summary.
Original example limitations
Unverified profile. Small sample, short duration and no body composition outcomes.
Terms explained
GH
Short for growth hormone.
Body composition
The amount of fat, muscle and other tissues in the body.
This link opens PubMed's search site, not a checked paper for this summary.
Compounds that increase growth hormone: unwanted effects
A text bringing together results from short studies carried out with supervision.
What did they want to find out?
What unwanted effects were described in these studies?
What does this example say?
The example says participants generally tolerated these compounds during the short studies.
What does this mean for you?
Observations over a short time do not prove a compound is safe in the long term. They are also not the same as using it without the study's supervision.
What we still do not know
We have not verified the sources behind this example. The summary does not include long-term safety. Before applying it to Ipamorelin, the compounds studied need to be checked.
Show example study details (not verified)
These details come from an example summary. We have not checked the original paper. They are not proof that a product works or is safe.
Example summary: safety of selective GH secretagogues
Growth Hormone & IGF Research · 2019
How it was studied
Narrative review. Pooled trial data.
Original example finding
Generally favorable tolerability in supervised, short-duration trials, according to the supplied summary.
Original example limitations
Unverified profile. The supplied summary does not include long-term safety data.
Terms explained
Tolerability
How participants coped with unwanted effects during a study.
GH secretagogue
A compound studied for triggering the release of growth hormone.
This link opens PubMed's search site, not a checked paper for this summary.
CJC-1295: hormone measurements and different variants
A comparison between groups of healthy young adults.
What did they want to find out?
Did the compound change growth hormone and another related measurement?
What does this example say?
The example says those measurements increased and stayed elevated.
What does this mean for you?
Hormone measurements do not prove better sports performance. The variant studied must be identified before comparing it with CJC-1295 No-DAC.
What we still do not know
We have not verified the article or the variant behind this example. A result from a DAC variant cannot automatically be transferred to a No-DAC variant. The summary also does not prove that combining it with Ipamorelin is safe or useful.
Show example study details (not verified)
These details come from an example summary. We have not checked the original paper. They are not proof that a product works or is safe.
Example summary: pharmacokinetics of GHRH analogues
Journal of Clinical Endocrinology & Metabolism · 2006
How it was studied
Randomized, placebo-controlled. n = 60 healthy adults.
Original example finding
Sustained increases in GH and IGF-1 in the dose groups, according to the supplied summary.
Original example limitations
Unverified profile. Healthy young adults only; no athletic performance outcomes. Verify the variant of the compound studied.
Terms explained
GH
Short for growth hormone.
IGF-1
Another hormone-related measurement in this example.
DAC / No-DAC
Names that distinguish variants of the compound. They should not be treated as identical.
This link opens PubMed's search site, not a checked paper for this summary.
A group of adults was observed; participants knew which treatment they received.
What did they want to find out?
How did growth hormone release change?
What does this example say?
The example says growth hormone returned to being released in pulses. It also says participants generally tolerated the treatment.
What does this mean for you?
A hormone change does not show that someone will have more energy, more muscle or better sleep. Older research does not prove these benefits either.
What we still do not know
We have not verified the article behind this example. The summary provides little information about changes in fat or muscle and does not prove benefits in healthy people.
Show example study details (not verified)
These details come from an example summary. We have not checked the original paper. They are not proof that a product works or is safe.
Example summary: Sermorelin and GH release in adults
Journal of Clinical Endocrinology & Metabolism · 1997
How it was studied
Open-label clinical series. n = 110 adults.
Original example finding
Restoration of pulsatile GH release with a favorable tolerability profile, according to the supplied summary.
Original example limitations
Unverified profile. Older literature and limited body composition outcomes.
Terms explained
Release in pulses
Release in separate rises, rather than at a constant level.
Open-label clinical series
Observation of a group of patients where the treatment they receive is not hidden.
This link opens PubMed's search site, not a checked paper for this summary.
A comparison between groups of adults with overweight or obesity.
What did they want to find out?
Did weight change differently with semaglutide than with a placebo?
What does this example say?
The example says the semaglutide group lost more weight, on average, than the placebo group.
What does this mean for you?
An average describes the group, not what will happen to each person. Losing weight does not mean that everything lost is fat.
What we still do not know
We have not verified the article behind this example. The summary mentions nausea and digestive problems. It also says some of the weight lost was not fat. It cannot establish whether treatment is suitable for a particular person.
Show example study details (not verified)
These details come from an example summary. We have not checked the original paper. They are not proof that a product works or is safe.
Example summary: weekly semaglutide in overweight or obesity
New England Journal of Medicine · 2021
How it was studied
Randomized, double-blind, placebo-controlled. n = 1,961 adults.
Original example finding
Mean weight reduction of 14.9% versus 2.4% with placebo over 68 weeks, according to the supplied summary.
Original example limitations
Unverified profile. Frequent nausea and gastrointestinal events; some of the weight lost was lean mass.
Terms explained
Placebo
A product without the compound being studied, used to compare results.
Average
A figure that summarizes the group. It is not a promise for each participant.
Lean mass
The part of the body that is not fat. It does not mean muscle alone.
This link opens PubMed's search site, not a checked paper for this summary.
Semaglutide in people who already had cardiovascular disease
Adults with overweight who already had heart or blood-vessel disease.
What did they want to find out?
Were there fewer serious cardiovascular problems in the semaglutide group?
What does this example say?
The example says there were fewer serious cardiovascular problems in that group.
What does this mean for you?
The result described concerns people who already had cardiovascular disease. It does not prove the same benefit in healthy people.
What we still do not know
We have not verified the article behind this example. The problems counted and any unwanted effects need to be checked. The summary cannot establish the balance of benefits and risks for a particular person.
Show example study details (not verified)
These details come from an example summary. We have not checked the original paper. They are not proof that a product works or is safe.
Example summary: semaglutide and cardiovascular outcomes
New England Journal of Medicine · 2023
How it was studied
Randomized cardiovascular outcomes trial. n = 17,604 adults.
Original example finding
Reduction in major cardiovascular events in adults with overweight and established disease, according to the supplied summary.
Original example limitations
Unverified profile. The population had pre-existing cardiovascular disease; results do not transfer to healthy people.
Terms explained
Cardiovascular
Related to the heart and blood vessels.
Study population
The type of people included. Their results do not automatically apply to everyone.
This link opens PubMed's search site, not a checked paper for this summary.
Epithalon: do changes in cells prove a longer life?
The summary describes groups of older people followed over time.
What did they want to find out?
They wanted to see whether certain cell measurements and measurements of the body's daily clock changed.
What does this example say?
The example says those measurements changed.
What does this mean for you?
Changing a measurement related to cells does not prove that a person will live longer.
What we still do not know
This example is unverified. The summary mainly uses older research and does not describe confirmation in modern trials that assign people to groups at random.
Show example study details (not verified)
These details come from an example summary. We have not checked the original paper. They are not proof that a product works or is safe.
Example summary: Epithalon, telomerase and circadian rhythms
Bulletin of Experimental Biology and Medicine · 2003
How it was studied
Cohort studies with prolonged follow-up. Multiple cohorts.
Original example finding
Telomerase activation and improvements in circadian markers reported in older cohorts, according to the supplied summary.
Original example limitations
Unverified profile. Mainly older, non-Western literature, without replication in modern randomized trials in the supplied summary.
Terms explained
Telomerase
An enzyme related to the ends of DNA. Measuring its activity is not the same as measuring years of life.
Circadian rhythm
The body's daily clock, related to cycles such as sleeping and being awake.
This link opens PubMed's search site, not a checked paper for this summary.
NAD+: did they study NAD+ or substances used to make it?
The summary describes a short trial in a small group of adults.
What did they want to find out?
They wanted to know what changed with substances the body can use to make NAD+. They checked available NAD+ and some measurements of how the body works.
What does this example say?
The example says more NAD+ was available. It also describes small changes in some measurements of metabolism.
What does this mean for you?
The trial describes substances the body can use to make NAD+, not a vial of NAD+. Those results do not prove what a NAD+ vial would do.
What we still do not know
This example is unverified. A short trial in a few people does not demonstrate lasting benefits or confirm results for other forms of NAD+.
Show example study details (not verified)
These details come from an example summary. We have not checked the original paper. They are not proof that a product works or is safe.
Example summary: NAD+ precursors and mitochondrial function
Cell Metabolism · 2018
How it was studied
Randomized crossover trial. n = 30 adults.
Original example finding
Greater NAD+ availability with modest changes in metabolic markers, according to the supplied summary.
Original example limitations
Unverified profile. Short duration and small sample; a precursor study does not prove outcomes for NAD+ in a vial.
Terms explained
NAD+ precursor
A substance the body can use to make NAD+. It is not NAD+ itself.
Metabolism
The body's processes for using and transforming energy.
This link opens PubMed's search site, not a checked paper for this summary.
Thymosin alpha-1: what did they measure in the immune system?
The summary combines trials in people with infections or receiving cancer-related care.
What did they want to find out?
They wanted to know whether some measurements of the immune response changed.
What does this example say?
The example says some measurements of that response improved in the situations studied.
What does this mean for you?
An immune-system measurement does not prove that someone gets ill less often. A result in one specific illness does not prove a benefit for everyone.
What we still do not know
This example is unverified. The illness and group studied need identifying before drawing conclusions. It does not demonstrate a general boost to immunity.
Show example study details (not verified)
These details come from an example summary. We have not checked the original paper. They are not proof that a product works or is safe.
Example summary: thymosin alpha-1 and immune modulation
Annals of the New York Academy of Sciences · 2012
How it was studied
Review of clinical trials. Multiple trials of authorized therapies, according to the supplied profile.
Original example finding
Improvements in immune response markers in trials of infections and oncology support, according to the supplied summary.
Original example limitations
Unverified profile. Effects depend on the condition studied; verify the country, indication and regulatory status.
Terms explained
Immune marker
A measurement of one aspect of the immune system. It is not, by itself, a result about how a person feels.
This link opens PubMed's search site, not a checked paper for this summary.